• Service
  • Resources
    • Webinars
    • Upcoming Events
    • Documents Download
    • FAQ
    • NMPA Approval Report
  • News
  • CER
  • About
Subscribe

Our Services

Strategy Consulting

  • Market Entry Strategy
  • Regulatory Strategy
  • Clinical Strategy
  • China Localization Strategy
  • Hainan Urgent Use Pathway
  • Innovation Pathway
  • Fast Track Pathway
  • Digital Health Consulting

Registration Affairs

  • Pre-market Registration
  • Modification Registration
  • Renewal Registration
  • Request for Classification
  • Legal Agent Representation
  • NMPA Expert Panel Meeting
  • NMPA Supplemental Notice

Quality Assurance

  • Postmarket Surveillance Compliance (IFU, Label, GSP)
  • Adverse Event Reporting
  • Recall Handling
  • Periodic Risk Evaluation Report
  • Annual QMS Self-Inspection Report
  • NMPA Inspections & Mock-Audit
  • QMS Establishment/Audit/Remediation
  • QA Gap Analysis
  • Factory Audit
  • Unique Device Identifier

Device Testing

  • China Local Type Testing
  • Device Modification Compliance Testing
  • Biocompatibility Testing
  • EMC Testing

Clinical Research Organization (CRO)

  • Clinical Trials/Research
  • Real-World Study
  • China CER & MDR CER
  • Clinical Evaluation Feasibility Assessment

Customized Training

  • China Regulatory Training
  • China QMS Training
  • China GCP Training
  • China Localization Training
  • Periodic Regulatory Updates Training

Other Services

  • Translation
  • Patent & Trademark
  • Distributor Evaluation & Audit
  • KOL Interview/Consultation
  • Investment
  • Global regulatory services
  • Service
  • Resources
    • Resources
    • Webinars
    • Upcoming Events
    • Documents Download
    • FAQ
    • NMPA Approval Report
  • News
  • About
  • CER
  • Subscribe
  • CN
  • US
  • Home
  • News
  • Other News

News


  • Moments
  • Regulations & Guidelines
  • Fast Track Update
  • QMS/PMS
  • Other News
  • NMPA Monthly Newsletter
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021

NMPA Collecting Public Comments On The Drafts Of Terms And Definitions For Medical Device Clinical Evaluation And IVD Clinical Performance Studies

2022-08-16

On August 10, 2022, NMPA issued a notice to collect public comments to establish industry standards of MD…

NMPA Notice On Special Review Procedures Of Innovative Medical Devices

2022-08-05

NMPA published Special Review Procedures Of Innovative Medical Devices on November 5, 2018. The implementation of this procedure…

China Supporting Hong Kong And Macao Medical Device Registrants To Produce Medical Devices In 9 Cities Of The Greater Bay Area

2022-08-04

To promote the reform of the medical device registrant system (Market Authorization Holder, MAH for short) in the…

Notice For Basic Principles Of Medical Device Safety And Performance Compliance Technical Guide Released

2022-08-01

On July 13, 2022, CMDE of NMPA issued a notice of the Compliance Technical Guideline of Essential Principles…

China NMPA Newsletter – June 2022

2022-07-31

Featured Articles NMPA New Approvals In June 2022 In June 2022, NMPA approved 193 medical devices, including 26…

NMPA New Approvals In June 2022

2022-07-29

In June 2022, NMPA approved 193 medical devices, including 26 Class III imported products, 25 Class II imported…

NMPA Collects Public Comments On Adjusting Medical Device Clinical Evaluation Catalog And IVD Clinical Trial Exemption Catalog

2022-07-13

On July 5, 2022, the NMPA issued a notice collecting public comments on the catalogues of medical devices…

China NMPA Newsletter – May 2022

2022-06-30

Featured Articles NMPA New Approvals In May 2022 In May 2022, NMPA approved 164 medical devices, including 23…

Post-market Periodic Risk Evaluation Report Mandatory For License Holder In China

2022-06-29

As per Measures for the Monitoring and Re-evaluation of Medical Device Adverse Events, NMPA has regulatory requirements for…

NMPA New Approvals In May 2022

2022-06-22

In May 2022, NMPA approved 164 medical devices, including 23 Class III imported products, 30 Class II imported…

China NMPA Newsletter – April 2022

2022-05-31

Featured Articles NMPA New Approvals In April 2022 In April 2022, NMPA approved 212 medical devices, including 35…

NMPA Enhances Cross-reginal MAH Surveillance

2022-05-30

The implementation of medical device MAH in China is aiming at promoting the reform of medical device review…
« Prev...246...910111213...1618...Next »
Twitter Linkedin
United States
Email: info@bradyknowsmedical.com
Phone: +86 18600382020
China
Beijing Office: Suite 301, Tower W3, Oriental Plaza, No. 1 East Chang'an Avenue, Dongcheng District, Beijing, China
Shanghai Office: Suite 1803, 18F, Park Place, No. 1601 West Nanjing Road, Jing'an District, Shanghai, China
Hainan Office: Boao Lecheng pilot zone of international medical tourism, Qionghai City, Hainan Province
Email: info@bradyknowsmedical.com
Phone: +86 18600382020

©2026 Bradynuoen Beijing PharmTech Co Ltd All Rights Reserved.

京ICP备15042665号-7